AR091273A1 - Inhibidores de pirimidinil tirosina quinasa - Google Patents

Inhibidores de pirimidinil tirosina quinasa

Info

Publication number
AR091273A1
AR091273A1 ARP130101980A AR091273A1 AR 091273 A1 AR091273 A1 AR 091273A1 AR P130101980 A ARP130101980 A AR P130101980A AR 091273 A1 AR091273 A1 AR 091273A1
Authority
AR
Argentina
Prior art keywords
optionally substituted
nitrogen
sulfur
oxygen
monocyclic heterocyclic
Prior art date
Application number
Other languages
English (en)
Original Assignee
Biogen Idec Inc
Sunesis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc, Sunesis Pharmaceuticals Inc filed Critical Biogen Idec Inc
Publication of AR091273A1 publication Critical patent/AR091273A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Abstract

Reivindicación 1: Un compuesto de fórmula (1) o una de sus sales aceptables desde el punto de vista farmacéutico, en donde: cada R¹ es en forma independiente hidrógeno, un grupo alifático C₁₋₆ sustituido en forma opcional, un grupo heterocíclico monocíclico de 3 - 7 miembros sustituido en forma opcional, o un grupo heterocicloalquilo sustituido en forma opcional que tiene 3 - 7 átomos de carbono y 1 - 3 heteroátomos seleccionados en forma independiente de nitrógeno, oxígeno, o azufre; o dos grupos R¹ se toman junto con sus átomos intervinientes para formar un anillo heterocíclico monocíclico parcialmente insaturado o saturado de 3 - 7 miembros sustituido en forma opcional que tiene 1 - 2 heteroátomos seleccionados en forma independiente de nitrógeno, oxígeno, o azufre; en donde los grupos opcionalmente sustituidos pueden sustituirse con halógeno, -NO₂, -CN, -OR, -SR, -N(R)₂, -C(O)R, -CO₂R, -N(R)C(O)OR, -C(O)N(R)₂, -OC(O)R, -N(R)C(O)R, -S(O)R, -S(O)₂R, o -S(O)₂N(R)₂; cada R es en forma independiente hidrógeno o alifático C₁₋₆; o dos grupos R unidos al mismo nitrógeno se toman junto con sus átomos intervinientes para formar un anillo heterocíclico monocíclico parcialmente insaturado o saturado de 3 - 7 miembros sustituido en forma opcional que tiene 1 - 2 heteroátomos, en los cuales un segundo heteroátomo se selecciona en forma independiente de nitrógeno, oxígeno, o azufre; el Anillo A es un compuesto de fórmula (2); R² es -Cl o -F; y R³ es -CF₃, -OCF₃, o -F.
ARP130101980 2012-06-08 2013-06-05 Inhibidores de pirimidinil tirosina quinasa AR091273A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261657360P 2012-06-08 2012-06-08

Publications (1)

Publication Number Publication Date
AR091273A1 true AR091273A1 (es) 2015-01-21

Family

ID=49712704

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130101980 AR091273A1 (es) 2012-06-08 2013-06-05 Inhibidores de pirimidinil tirosina quinasa

Country Status (30)

Country Link
US (5) US9394277B2 (es)
EP (3) EP3385263B1 (es)
JP (6) JP6214643B2 (es)
KR (4) KR102468430B1 (es)
CN (3) CN109305959B (es)
AR (1) AR091273A1 (es)
AU (5) AU2013271407B2 (es)
BR (2) BR112014030655B1 (es)
CA (2) CA2875799C (es)
CY (1) CY1120638T1 (es)
DK (1) DK2858499T3 (es)
EA (2) EA201790418A1 (es)
ES (2) ES2684268T3 (es)
HK (1) HK1209284A1 (es)
HR (1) HRP20181294T1 (es)
HU (1) HUE039897T2 (es)
IL (2) IL235938B (es)
IN (1) IN2014DN10576A (es)
LT (1) LT2858499T (es)
MX (2) MX363672B (es)
NZ (1) NZ702715A (es)
PH (2) PH12014502699B1 (es)
PL (1) PL2858499T3 (es)
PT (1) PT2858499T (es)
RS (1) RS57978B1 (es)
SG (2) SG11201408173WA (es)
SI (1) SI2858499T1 (es)
TW (3) TWI592406B (es)
WO (1) WO2013185084A1 (es)
ZA (1) ZA201409255B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2473049T3 (pl) 2009-09-04 2019-07-31 Biogen Ma Inc. Inhibitory kinazy tyrozynowej brutona
WO2012058645A1 (en) 2010-10-29 2012-05-03 Biogen Idec Ma Inc. Heterocyclic tyrosine kinase inhibitors
AR091273A1 (es) 2012-06-08 2015-01-21 Biogen Idec Inc Inhibidores de pirimidinil tirosina quinasa
US9353087B2 (en) 2012-06-08 2016-05-31 Biogen Ma Inc. Inhibitors of Bruton's tyrosine kinase
RS57662B1 (sr) * 2013-12-11 2018-11-30 Biogen Ma Inc Biaril jedinjenja korisna za lečenje humanih bolesti u onkologiji, neurologiji i imunologiji
WO2015151006A1 (en) 2014-03-29 2015-10-08 Lupin Limited Substituted purine compounds as btk inhibitors
WO2015170266A1 (en) 2014-05-07 2015-11-12 Lupin Limited Substituted pyrimidine compounds as btk inhibitors
CA2965517C (en) * 2014-10-24 2023-05-02 Bristol-Myers Squibb Company Indole carboxamides compounds useful as kinase inhibitors
KR20190035769A (ko) * 2016-07-21 2019-04-03 바이오젠 엠에이 인코포레이티드 브루톤 타이로신 카이나제 저해제의 석신에이트 형태 및 조성물
US20210113568A1 (en) 2018-04-27 2021-04-22 Ono Pharmaceutical Co., Ltd. PREVENTIVE AND/OR THERAPEUTIC AGENT FOR AUTOIMMUNE DISEASE COMPRISING COMPOUND HAVING Btk INHIBITORY ACTIVITY AS ACTIVE INGREDIENT
CA3224949A1 (en) 2018-07-31 2020-02-06 Loxo Oncology, Inc. Spray-dried dispersions, formulations, and polymorphs of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1h-pyrazole-4-carboxamide
WO2020188015A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
WO2021089791A1 (en) 2019-11-08 2021-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
US20240100172A1 (en) 2020-12-21 2024-03-28 Hangzhou Jijing Pharmaceutical Technology Limited Methods and compounds for targeted autophagy
WO2022212893A1 (en) 2021-04-02 2022-10-06 Biogen Ma Inc. Combination treatment methods of multiple sclerosis
WO2023081715A1 (en) 2021-11-03 2023-05-11 Viracta Therapeutics, Inc. Combination of car t-cell therapy with btk inhibitors and methods of use thereof
WO2023081709A1 (en) 2021-11-03 2023-05-11 Viracta Therapeutics, Inc. Vecabrutinib for the treatment of graft-versus-host disease
WO2023110970A1 (en) 2021-12-14 2023-06-22 Netherlands Translational Research Center Holding B.V Macrocyclic btk inhibitors

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1624A (en) * 1840-06-10 Cooking-stove
US4528138A (en) 1984-06-20 1985-07-09 E. R. Squibb & Sons, Inc. 16-Keto-17-substituted thia-17-alkyl(or alkenyl or alkynyl) androstenes
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
EP0495421B1 (en) 1991-01-15 1996-08-21 Alcon Laboratories, Inc. Use of carrageenans in topical ophthalmic compositions
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
PA8474101A1 (es) 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
US6919178B2 (en) 2000-11-21 2005-07-19 Sunesis Pharmaceuticals, Inc. Extended tethering approach for rapid identification of ligands
AU2001250849A1 (en) 2000-03-17 2001-10-03 Bristol-Myers Squibb Pharma Company Cyclic beta-amino acid derivatives as inhibitors of matrix metalloproteases and tnf-alpha
MY137020A (en) 2000-04-27 2008-12-31 Abbott Lab Diazabicyclic central nervous system active agents
EP1294724B1 (en) 2000-06-26 2006-04-19 Pfizer Products Inc. Pyrrolo¬2,3-d|pyrimidine compounds as immunosuppressive agents
PE20020507A1 (es) * 2000-10-17 2002-06-25 Schering Corp Compuestos no-imidazoles como antagonistas del receptor histamina h3
US20050143372A1 (en) * 2001-10-30 2005-06-30 Shomir Ghosh Compounds, pharmaceutical compositions and methods of use therefor
JP2005515173A (ja) 2001-10-31 2005-05-26 バイエル・ヘルスケア・アクチェンゲゼルシャフト ピリミド［４，５−ｂ］インドール誘導体
DE602004009295T2 (de) 2003-01-14 2008-07-03 Arena Pharmaceuticals, Inc., San Diego 1,2,3-trisubstituierte aryl- und heteroarylderivate als modulatoren des metabolismus zur vorbeugung und behandlung von metabolismus-bedingten krankheiten wie diabetes oder hyperglykämie
SI1678166T1 (sl) 2003-10-14 2009-10-31 Univ Arizona State Inhibitorji proteinske kinaze
EP1778298A4 (en) * 2004-04-01 2010-03-31 Univ Pennsylvania LIPOPROTEIN-NANO PLATFORMS
EP1750727A2 (en) 2004-04-23 2007-02-14 Exelixis, Inc. Kinase modulators and methods of use
FR2870541B1 (fr) 2004-05-18 2006-07-14 Proskelia Sas Derives de pyrimidines antigonistes du recepteur de la vitronectine
TW200621760A (en) 2004-09-09 2006-07-01 Mitsubishi Pharma Corp 2-morpholino-4-pyrimidone compound
NZ555236A (en) * 2004-11-04 2010-10-29 Vertex Pharma Pyrazolo[1,5-a]pyrimidines useful as inhibitors of protein kinases
KR101351209B1 (ko) 2004-12-03 2014-02-06 머크 샤프 앤드 돔 코포레이션 Ｃｂ1 길항제로서 치환된 피페라진
CA2590961C (en) 2004-12-28 2013-11-26 Exelixis, Inc. [1h-pyrazolo[3,4-d]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-threonine kinase modulators (p70s6k, atk1 and atk2) for the treatment of immunological, inflammatory and proliferative diseases
US7880002B2 (en) 2004-12-29 2011-02-01 Millennium Pharmaceuticals, Inc. Substituted piperazinyl-pyrrolidine compounds useful as chemokine receptor antagonists
WO2006091450A1 (en) * 2005-02-18 2006-08-31 Lexicon Genetics Incorporated 4-piperidin-1-yl-7h-pyrrolo[2,3-d]pyrimidine compounds
US20060281764A1 (en) 2005-06-10 2006-12-14 Gaul Michael D Aminopyrimidines as kinase modulators
US20060281700A1 (en) 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using aminopyrimidines kinase modulators
TW200740779A (en) 2005-07-22 2007-11-01 Mitsubishi Pharma Corp Intermediate compound for synthesizing pharmaceutical agent and production method thereof
JP5191391B2 (ja) 2005-11-01 2013-05-08 ターゲジェン インコーポレーティッド キナーゼのビ−アリールメタ−ピリミジン阻害剤
CN101378807A (zh) * 2005-12-21 2009-03-04 先灵公司 H3拮抗剂/反相激动剂与食欲抑制剂的组合
US20080076924A1 (en) 2006-06-30 2008-03-27 Patrick Betschmann Piperazines as P2X7 antagonists
WO2008012635A2 (en) 2006-07-26 2008-01-31 Pfizer Products Inc. Amine derivatives useful as anticancer agents
EP2059305A2 (en) 2006-07-26 2009-05-20 Novartis Ag Inhibitors of undecaprenyl pyrophosphate synthase
US20100160292A1 (en) 2006-09-11 2010-06-24 Cgi Pharmaceuticals, Inc Kinase Inhibitors, and Methods of Using and Identifying Kinase Inhibitors
SI2526934T1 (sl) 2006-09-22 2016-04-29 Pharmacyclics Llc Inhibitorji Bruton tirozin kinaze
AR065494A1 (es) * 2007-03-02 2009-06-10 Schering Corp Derivados de piperidina y metodos de uso de los mismos
WO2008116064A2 (en) 2007-03-21 2008-09-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful for the treatment of proliferative, allergic, autoimmune or inflammatory diseases
WO2008144253A1 (en) 2007-05-14 2008-11-27 Irm Llc Protein kinase inhibitors and methods for using thereof
JP5291095B2 (ja) 2007-06-01 2013-09-18 グラクソスミスクライン エルエルシー イミダゾピリジンキナーゼ阻害剤
RU2505538C2 (ru) * 2008-02-05 2014-01-27 Ф.Хоффманн-Ля Рош Аг Новые пиридиноны и пиридазиноны
ES2542066T3 (es) 2008-04-29 2015-07-30 Immunexcite, Inc. Composiciones inmunomoduladoras y métodos de uso de las mismas
AU2009270856B2 (en) 2008-07-16 2013-07-25 Pharmacyclics Llc Inhibitors of Bruton's tyrosine kinase for the treatment of solid tumors
WO2010068788A1 (en) * 2008-12-10 2010-06-17 Cgi Pharmaceuticals, Inc. Heterocyclic amides as btk inhibitors
KR20110098827A (ko) * 2008-12-19 2011-09-01 브리스톨-마이어스 스큅 컴퍼니 키나제 억제제로서 유용한 카르바졸 카르복스아미드 화합물
WO2010080712A2 (en) * 2009-01-06 2010-07-15 Dana Farber Cancer Institute Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders
EP2435442B1 (de) 2009-05-25 2016-01-13 Sandoz AG Verfahren zur herstellung von ceftobiprol medocaril
EP2485589A4 (en) 2009-09-04 2013-02-06 Biogen Idec Inc HETEROARYARY INHIBITORS OF BTK
PL2473049T3 (pl) 2009-09-04 2019-07-31 Biogen Ma Inc. Inhibitory kinazy tyrozynowej brutona
US8685880B2 (en) 2010-06-30 2014-04-01 Chevron U.S.A. Inc. On-site drying of aqueous salt for ionic liquid make-up
WO2012058645A1 (en) 2010-10-29 2012-05-03 Biogen Idec Ma Inc. Heterocyclic tyrosine kinase inhibitors
US9353087B2 (en) 2012-06-08 2016-05-31 Biogen Ma Inc. Inhibitors of Bruton's tyrosine kinase
AR091273A1 (es) * 2012-06-08 2015-01-21 Biogen Idec Inc Inhibidores de pirimidinil tirosina quinasa
EP3444251B1 (en) 2013-12-11 2023-06-07 Biogen MA Inc. Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
RS57662B1 (sr) 2013-12-11 2018-11-30 Biogen Ma Inc Biaril jedinjenja korisna za lečenje humanih bolesti u onkologiji, neurologiji i imunologiji
US20170298446A1 (en) 2014-10-03 2017-10-19 Ohio State Innovation Foundation Biomarkers of bruton tyrosine kinase inhibitor resistance

Also Published As

Publication number Publication date
EA201492056A1 (ru) 2015-05-29
MX363672B (es) 2019-03-29
PL2858499T3 (pl) 2019-03-29
AU2017201536B2 (en) 2019-03-07
SG11201408173WA (en) 2015-01-29
MX2014015044A (es) 2015-09-22
SG10201708535UA (en) 2017-11-29
AU2019203476A1 (en) 2019-06-06
KR102468430B1 (ko) 2022-11-21
EP3753934A1 (en) 2020-12-23
AU2021202412A1 (en) 2021-05-20
BR122021002178B1 (pt) 2022-03-22
IL235938A0 (en) 2015-02-01
KR20200043497A (ko) 2020-04-27
IL235938B (en) 2020-10-29
AU2022275504A1 (en) 2023-01-05
TWI592406B (zh) 2017-07-21
IN2014DN10576A (es) 2015-08-28
NZ702715A (en) 2016-11-25
CA2875799C (en) 2021-03-23
CN109305959A (zh) 2019-02-05
TW202142535A (zh) 2021-11-16
PH12018501463A1 (en) 2019-03-04
US20210017155A1 (en) 2021-01-21
AU2019203476B2 (en) 2021-01-28
RS57978B1 (sr) 2019-01-31
TW201805279A (zh) 2018-02-16
TWI792158B (zh) 2023-02-11
KR20150036020A (ko) 2015-04-07
JP2021073299A (ja) 2021-05-13
BR112014030655A8 (pt) 2018-01-02
DK2858499T3 (en) 2018-08-20
CA3108186A1 (en) 2013-12-12
JP2019077728A (ja) 2019-05-23
US20190047986A1 (en) 2019-02-14
PH12014502699A1 (en) 2015-02-02
TWI719209B (zh) 2021-02-21
JP6214643B2 (ja) 2017-10-18
JP2023052415A (ja) 2023-04-11
CA2875799A1 (en) 2013-12-12
AU2013271407B2 (en) 2016-12-08
SI2858499T1 (sl) 2018-10-30
CN104540385B (zh) 2018-06-05
LT2858499T (lt) 2018-09-10
EP3385263B1 (en) 2020-07-22
JP2017193583A (ja) 2017-10-26
EP2858499A4 (en) 2016-01-20
IL277951A (en) 2020-11-30
EP2858499A1 (en) 2015-04-15
EA201790418A1 (ru) 2017-11-30
WO2013185084A1 (en) 2013-12-12
EA027823B1 (ru) 2017-09-29
ZA201409255B (en) 2015-12-23
BR112014030655A2 (pt) 2017-06-27
US9944622B2 (en) 2018-04-17
JP2015518903A (ja) 2015-07-06
HUE039897T2 (hu) 2019-02-28
KR20220154850A (ko) 2022-11-22
CN109305959B (zh) 2022-02-08
PT2858499T (pt) 2018-10-24
MX2019003618A (es) 2019-07-18
EP3385263A1 (en) 2018-10-10
KR102102587B1 (ko) 2020-04-22
KR20210072139A (ko) 2021-06-16
JP2021073298A (ja) 2021-05-13
ES2834333T3 (es) 2021-06-17
ES2684268T3 (es) 2018-10-02
CY1120638T1 (el) 2019-12-11
US10618887B2 (en) 2020-04-14
AU2013271407A1 (en) 2015-01-22
CN104540385A (zh) 2015-04-22
EP2858499B1 (en) 2018-05-16
AU2017201536A1 (en) 2017-03-23
US20230174511A1 (en) 2023-06-08
PH12014502699B1 (en) 2015-02-02
CN113549055A (zh) 2021-10-26
US20150158843A1 (en) 2015-06-11
BR112014030655B1 (pt) 2021-04-20
US20160304494A1 (en) 2016-10-20
TW201410668A (zh) 2014-03-16
HRP20181294T1 (hr) 2018-10-05
US9394277B2 (en) 2016-07-19
HK1209284A1 (en) 2016-04-01

Similar Documents

Publication Publication Date Title
AR091273A1 (es) Inhibidores de pirimidinil tirosina quinasa
CY1119585T1 (el) Ενωσεις τετραϋδροπυρρολοθειαζινης
AR098136A1 (es) Compuestos de heteroarilo como inhibidores de btk y usos de los mismos
DOP2019000083A (es) COMPUESTOS DE BENZO[b]TIOFENO COMO AGONISTAS DE STING
AR103138A1 (es) Compuestos de heteroarilo como inhibidores de la irak y usos de los mismos
CY1120705T1 (el) Καινοφανεις αναστολεις αποακετυλασων ιστονων
CU24517B1 (es) Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos
CY1121677T1 (el) Ενωσεις διμεθυλοβενζοϊκου οξεος
AR090928A1 (es) Compuestos de hexahidropirano[3,4-d][1,3]tiazin-2-amina heterociclicos sustituidos
AR107694A1 (es) Heteroarilos inhibidores de pad4
AR106141A1 (es) Métodos e intermediarios para la preparación de derivados de ácidos biliares
CR20150472A (es) USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRANSTORNOS RELACIONADOS CON LA PI3Kd
AR093598A1 (es) Compuestos y sus metodos de empleo
UY35573A (es) Derivados de sulfamoilpirrolamida y su uso como m edicamentos para el tratamiento de la hepatitis b
AR100809A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
CR20140548A (es) Derivados de aril-sultamo como moduladores de rorc
AR099379A1 (es) Compuestos tricíclicos como agentes antineoplásicos
NI201200191A (es) Derivados de indolizina, su procedimiento de preparación y su aplicación en terapéutica
CR20200276A (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamientos de la hepatitis b (divisional exp. 2015-0059)
EA201591634A1 (ru) Дигидропиридопиримидиновые соединения
CR20150419A (es) Derivados sustituidos del ácido bisfenil butanóico fosfónico como inhibidores de la nep
AR094852A1 (es) Oestra-1,3,5(10),16-tetraeno-3-carboxamidas
AR098432A1 (es) Compuestos heterocíclicos
AR103742A1 (es) Derivados de trifluorometilpropanamida
CU20170007A7 (es) Compuestos de imidazopiridazina

Legal Events

Date Code Title Description
FC Refusal